Infections following orthotopic liver transplantation.
The epidemiology of infections associated with orthotopic liver transplantation is summarized herein, and approaches to prophylaxis are outlined. Infection is a major complication following orthotopic liver transplantation, and more than half of transplant recipients develop at least one infection. The risk of infection is highest in the first month after transplantation, and the most common pathogens are bacteria and cytomegalovirus (CMV). Bacterial infections usually occur in the first month, arise in the abdomen, and are caused by aerobes. The peak incidence of CMV infection is late in the first month and early in the second month after transplantation. CMV syndromes include fever and neutropenia, hepatitis, pneumonitis, gut ulceration, and disseminated infection. Other significant problems are Candida intraabdominal infection, Herpes simplex mucocutaneous infection or hepatitis, adenovirus hepatitis, and Pneumocystis carinii pneumonia. Prophylaxis of infection in liver transplant recipients has not been well-studied. Several different regimens of parenteral, oral absorbable, and/or oral non-absorbable antibiotics active against bacteria and yeast have been used at various centers, but no randomized controlled trials have been conducted. Selective bowel decontamination appears to be a promising approach to the prevention of bacterial and Candida infections, while oral acyclovir may be a relatively convenient and effective agent for CMV prophylaxis.
Arnow
P M
PM
Department of Medicine, University of Chicago, Illinois 60637.
D000212:Acyclovir / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007239:Infections / Q000209:etiology*; D016031:Liver Transplantation; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D010272:Parasitic Diseases / Q000209:etiology / Q000517:prevention & control; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication; D012307:Risk Factors; D013997:Time Factors; D014777:Virus Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy
D000900:Anti-Bacterial Agents; D000212:Acyclovir